NEW YORK–(BUSINESS WIRE)–Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Robert Mashal, M.D. to its Board of Directors.
“We are delighted to have Dr. Mashal join our Board of Directors,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. “Robert is a seasoned biotech industry veteran and his experience as an investor, operator, and medical oncologist will provide us with valuable insights. We look forward to working with Robert to advance Nuvation’s pipeline.”
“Nuvation Bio is at the forefront of developing therapeutic candidates to treat the unmet need in oncology, highlighted by the company’s novel drug-drug conjugate platform,” said Robert Mashal, M.D. “I am excited to leverage my past experiences to help the Board and management bring innovative oncology therapeutics to patients.”
Robert currently serves as a consultant to the life sciences industry. Previously, he was the Global Head of Strategy for the Immunology and Oncology franchises at Sanofi. Robert has worked as CEO of NKT Therapeutics and Alinea Pharmaceuticals, two venture capital backed life sciences firms. He was a partner at Boston Millennia Partners, a private equity firm, where he was on the Board of Directors of Glycofi, Cardiomems, and Sapphire Therapeutics. He served as a Program Executive at Vertex Pharmaceuticals, where he was on the Joint Steering Committee for the Vertex-Novartis kinase collaboration. He was also a consultant at McKinsey and Company. Prior to McKinsey, Dr. Mashal was a board-certified medical oncologist and received his training in internal medicine at the University of California, San Francisco, and in oncology at the Dana-Farber Cancer Institute. Dr. Mashal received his B.A. and M.D. degrees from Johns Hopkins University.
About Nuvation Bio
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com.